Our team is on a mission to improve outcomes in cancer treatment

Meet the Team

Management Team

  • Mary T. Szela

    CEO and President
  • Bryan F. Cox, Ph.D

    Chief of Research
  • Scott Davie

    Chief Technology Officer
  • Anni Goldberg

    General Counsel/Chief HR Officer
  • Lynne Aronson

    VP of Regulatory and Quality
  • Lynne Aronson

    VP of Regulatory and Quality
  • Mary T. Szela

    CEO and President

    Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record. Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Ms. Szela held ascending management positions at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences. She earned an M.B.A. and a B.S. in nursing, both from the University of Illinois.

  • Bryan F. Cox, Ph.D

    Chief of Research

    Over 30 years of R&D experience in Large Pharma, Small Pharma, and Biotech companies.

    Has participated in advancing over 60 compounds from Discovery to Phase I clinical trials. Is an adjunct Professor at the University of Iowa College of Medicine with over 100 peer-reviewed publications.

  • Scott Davie

    Chief Technology Officer

    Scott Davie has more than 25 years of medical device experience, creating and leading teams to deliver innovative, complex, high quality systems from conceptualization to market launch and end of life cycle, having spent the majority of his career at Medtronic. He possesses a deep understanding of clinical workflow and use cases across a variety of medical specialties. Throughout his career, he has developed implantable defibrillators, pacemakers, and pressure sensors; ablation catheters and consoles. His regulatory experience includes 510k's, PMA-S, original PMAs, and CE Marks, and has global experience having lived in Spain, Japan, and Canada.

    Scott earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.

  • Anni Goldberg

    General Counsel/Chief HR Officer

    With experience in private practice, in house counsel and non-profit senior leadership roles, Anni has broad litigation experience in both state and federal jurisdictions in a wide breadth of litigation matters. Prior to her work with TriSalus Life Sciences, Anni was most recently of counsel at Katten & Temple, a boutique litigation law firm. Anni provided legal counsel on a variety of federal civil litigation matters to senior executives as well as conducting internal employment investigations. A majority of Anni's clients have been in the pharmaceutical and medical device industry.

    Prior to joining Katten & Temple, Anni was President of a not-for-profit company, Counsel for Abbott Laboratories, an associate for Kelley, Drye & Warren and Kirkland & Ellis. She has also served on a variety of not-for-profit boards.

    Anni received her JD from the University of Wisconsin graduating Cum Laude, Order of the Coif and Dean's List.

Board of Directors

  • Mats L. Wahlström

    Chairman
  • Karen Cassidy

    Director
  • Yongxin Han, PhD

    Director
  • Gene McGrevin

    Director
  • Diane Parks

    Director
  • Anil Singhal

    Director
  • Simone Song

    Director
  • John L. Tullis

    Director
  • Mary T. Szela

    Director
  • Mats L. Wahlström

    Chairman

    Mr. Wahlström has more than 30 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field. Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of PCI | HealthDev, and Chairman of Caduceus Medical Holdings, Inc. He also serves as the Lead Director and Chairman of the Audit/Finance Committee of Coherus Biosciences, a public biotech company. In addition, he currently serves on the boards of Getinge AB and Alteco Medical AB, both public companies, as well as Triomed AB and Circuit Clinical, Inc.

    Mats served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010. From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President and CEO of Gambro North America as well as CFO of the Gambro Group.

  • Karen Cassidy

    Director

    Ms. Cassidy began her career in a start-up at Johnson & Johnson, the Dermatological Division. She spent six years at Xerox, initially as Sales Operation Planning Manager for the U.S., then running worldwide operations for this function, followed by a two-year stint in the field as a Sales Manager. After this operating background, Ms. Cassidy joined Oak Investment Partners for seven years and subsequently co-managed Aetna's Venture Capital Fund. Ms. Cassidy then returned to the operating side in 1991, assuming the CEO role at ImplaMed and VP Business Development roles at Symbiosis and Corvita, which were sold within a seven-year period. As Managing Director at Partisan Management, Ms. Cassidy has recruited and mentored the management team for each company and applied her sales, marketing, and business development expertise to the building of the company. Ms. Cassidy also manages the liquidity events for the Partisan Management companies.

  • Yongxin Han, PhD

    Director

    Dr. Yongxin Han has more than 20 years of research and management experience in pharmaceutical industry. Dr. Han was a Senior Group Leader at Array Biopharma, the cofounder and General Manager of Chemizon and Centaurus BioPharma, and has delivered more than 14 investigational new drug applications. He has been the "Beijing Overseas Talent Plan" winner and was awarded "Beijing Distinguished Experts" and "Beijing One Hundred Leading Talents of Science and Technology."

    Dr. Han is currently a Partner with Lapam Capital LLC, a healthcare Venture Capital firm, and Board Director of BroadenBio Co. Ltd. and VivaVision Co. Ltd. He received his Bachelor of Science from Peking University, Master of Science from the Chinese Academy of Science, and Ph.D. from University of Minnesota.

  • Gene McGrevin

    Director

    With more than 25 years of experience in the medical industry, Gene McGrevin has held senior management positions in global companies including Johnson & Johnson and Kimberly-Clark Corporation. Mr. McGrevin also was instrumental in the expansion and sale of several medical startups.  They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard).  In addition, Mr. McGrevin serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics. Mr. McGrevin holds an MBA from the University of Pennsylvania's Wharton School.  He earned a BA in economics at the University of Pittsburgh.

  • Diane Parks

    Director

    Diane Parks has more than 30 years of success across the biotech, pharmaceutical, and advertising industries. Throughout her executive career, Diane has held commercial leadership positions at companies including Kite Pharma Inc, Pharmacyclics, Amgen, and Genentech. Most recently Diane served as SVP, Marketing & Account Management at Kite Pharma Inc, where she successfully led the development of the commercial organization and the launch of the first CAR-T product, YESCARTA.

    Diane holds a Master of Business Administration in Marketing from Georgia State University and received her Bachelor of Arts in Marketing from Kansas State University. Diane currently serves as a member of the Board for Calliditas Therapeutics, an early stage pharmaceutical company based in Stockholm, Sweden.

  • Anil Singhal

    Director

    Dr. Singhal is the former Vice President of Early Oncology Development at AbbVie and Head of AbbVie-Redwood City site. During his tenure at AbbVie, he oversaw the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases. Anil has held senior roles in the US, Japanese and German biopharma / biotechnology industry for over 30 years leading to the approval of Prosorba in rheumatoid arthritis and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.

    Anil is passionate about the translation of novel science into transforming medicines for cancer patients. Anil holds a Ph.D. from Wakesman Institute of Rutgers University and an Executive MBA from University of Washington.

  • Simone Song

    Director

    Mrs. Song has more than 25 years of experience in the healthcare sector. Simone is the Founder and Senior Partner of ORI Capital and the former Head of Goldman Sachs Healthcare Investment Banking for Greater China.

    Prior to joining Goldman Sachs, Simone was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings.

    Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.

  • John L. Tullis

    Director

    Mr. Tullis is President and a Partner at Tullis Health Investors, where he is focused especially on healthcare technology and services, medical devices, and international markets. He has more than 19 years of investing and international business experience. Mr. Tullis currently serves as Chairman of CareSync, Inc. and was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade's Economic Development Organization, for three years.

    Mr. Tullis hold a Bachelor's degree in Liberal Arts from DePauw University. He received a Graduate Certificate from the University of Virginia's McIntire Business Institute, and a Master's degree in Business Administration from the University of Miami. At ages 14-15, he studied at a Taiwanese boarding school, where he was the school's only non-Chinese student.

  • Mary T. Szela

    Director

    Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record. Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Ms. Szela held ascending management positions at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences. She earned an M.B.A. and a B.S. in nursing, both from the University of Illinois.